Prothena Corporation plc (LON:0Y3M)

Market Cap	335.93M -22.2%
Revenue (ttm)	39.72M +347.4%
Net Income	-18.05M
EPS	-0.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13
Open	8.33
Previous Close	8.48
Day's Range	8.33 - 8.33
52-Week Range	7.82 - 11.66
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 67
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0Y3M

Financial Performance

In 2025, Prothena Corporation's revenue was $9.68 million, a decrease of -92.83% compared to the previous year's $135.16 million. Losses were -$244.09 million, 99.6% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error